SG11202003800YA - Zika vaccines and immunogenic compositions, and methods of using the same - Google Patents

Zika vaccines and immunogenic compositions, and methods of using the same

Info

Publication number
SG11202003800YA
SG11202003800YA SG11202003800YA SG11202003800YA SG11202003800YA SG 11202003800Y A SG11202003800Y A SG 11202003800YA SG 11202003800Y A SG11202003800Y A SG 11202003800YA SG 11202003800Y A SG11202003800Y A SG 11202003800YA SG 11202003800Y A SG11202003800Y A SG 11202003800YA
Authority
SG
Singapore
Prior art keywords
methods
same
immunogenic compositions
zika vaccines
zika
Prior art date
Application number
SG11202003800YA
Inventor
Jill A Livengood
Holli Giebler
Whitney Baldwin
Hansi Dean
Claire Y H Kinney
Original Assignee
Takeda Vaccines Inc
The United States Of America As Represented By The Secretary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc, The United States Of America As Represented By The Secretary filed Critical Takeda Vaccines Inc
Publication of SG11202003800YA publication Critical patent/SG11202003800YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SG11202003800YA 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same SG11202003800YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581500P 2017-11-03 2017-11-03
US201762592995P 2017-11-30 2017-11-30
PCT/US2018/059219 WO2019090228A2 (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same

Publications (1)

Publication Number Publication Date
SG11202003800YA true SG11202003800YA (en) 2020-05-28

Family

ID=64427224

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11202003949TA SG11202003949TA (en) 2017-11-03 2018-11-05 Method for inactivating zika virus and for determining the completeness of inactivation
SG11202003796XA SG11202003796XA (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same
SG11202003800YA SG11202003800YA (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG11202003949TA SG11202003949TA (en) 2017-11-03 2018-11-05 Method for inactivating zika virus and for determining the completeness of inactivation
SG11202003796XA SG11202003796XA (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same

Country Status (12)

Country Link
US (5) US11478541B2 (en)
EP (3) EP3703739A2 (en)
JP (4) JP2021502350A (en)
KR (3) KR20200085302A (en)
CN (3) CN111526885A (en)
AU (6) AU2018359558C1 (en)
BR (3) BR112020008652A2 (en)
CA (3) CA3081586A1 (en)
MX (3) MX2020004543A (en)
MY (2) MY194449A (en)
SG (3) SG11202003949TA (en)
WO (3) WO2019090228A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019090228A2 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN111601885A (en) 2017-11-30 2020-08-28 武田疫苗股份有限公司 Methods for inactivating Zika virus and related methods
EP3965811A1 (en) * 2019-05-08 2022-03-16 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
US20230324404A1 (en) 2020-05-20 2023-10-12 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
US20240133887A1 (en) 2020-10-08 2024-04-25 Takeda Vaccines, Inc. Methods for determining complement-fixing antibodies
CN112980805B (en) * 2021-02-25 2022-11-08 中国科学院广州生物医药与健康研究院 Recombinant Zika virus attenuated strain and preparation method and application thereof
CN112941201B (en) * 2021-03-01 2022-03-08 武汉珈创生物技术股份有限公司 Mixed primer for multi-cell species identification and cross contamination detection and use method thereof
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
KR102619184B1 (en) * 2022-12-27 2023-12-29 주식회사 그린백스 Vaccine composition comprising Zika virus inactivated by Epigallocatechin-3-gallate as an active ingredient

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
DK0382271T3 (en) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler as adjuvants in vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (en) 1989-07-03 1991-10-25 Seppic Sa INJECTABLE MULTIPHASIC EMULSIONS
FR2649013B1 (en) 1989-07-03 1991-10-25 Seppic Sa VACCINES AND VECTORS OF FLUID ACTIVE INGREDIENTS CONTAINING METABOLIZABLE OIL
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CN1087176C (en) 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ES2267100T5 (en) 1994-07-15 2011-04-08 The University Of Iowa Research Foundation IMMUNOMODULATING OLIGONUCLEOTIDES.
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
DE19612966B4 (en) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK cells and methods of propagating influenza viruses
DE19612967A1 (en) 1996-04-01 1997-10-02 Behringwerke Ag Process for the propagation of influenza viruses in cell culture, and the influenza viruses obtainable by the process
WO1997048440A1 (en) 1996-06-18 1997-12-24 Alza Corporation Device for enhancing transdermal agent delivery or sampling
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ES2195190T3 (en) 1996-12-20 2003-12-01 Alza Corp DEVICE AND METHOD FOR IMPROVING THE TRANSDERMAL AGENT FLOW.
AT405939B (en) 1997-02-24 1999-12-27 Immuno Ag METHOD FOR INACTIVATING LIPID-ENVIRONED VIRUSES
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
ES2382946T3 (en) 1997-08-28 2012-06-14 Cj Cheiljedang Corporation Japanese attenuated encephalitis virus
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ES2298316T3 (en) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. WATER OIL EMULSIONS CONTAINING SAPONINS.
EP1021548A1 (en) 1997-10-07 2000-07-26 University Of Maryland Biotechnology Institute Method for introducing and expressing rna in animal cells
WO1999027961A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
PL354714A1 (en) 1998-04-09 2004-02-09 Smithkline Beecham Biologicals S.A. Adjuvant compositions
ES2257068T3 (en) 1998-08-10 2006-07-16 Antigenics Inc. CPG AND SAPONINAS ASSISTANT MIXTURES AND EMPLOYMENT METHODS OF THE SAME.
US6703233B1 (en) 1998-12-02 2004-03-09 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
US7056700B2 (en) 2000-11-22 2006-06-06 University Of Maryland Use of ClyA hemolysin for excretion of proteins
GB0326439D0 (en) 2003-11-13 2003-12-17 Imp College Innovations Ltd Methods
US20080193478A1 (en) 2004-08-27 2008-08-14 Rajesh Jain Inactivated Poliomyelitis Vaccine Derived From Sabin Strain Of Polio Virus
ES2386272T3 (en) 2004-09-09 2012-08-16 Novartis Vaccines And Diagnostics Gmbh Reduction of potential iatrogenic risks associated with influenza vaccines
EP1724338A1 (en) 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
EP2073839B1 (en) 2006-09-01 2016-10-19 Bharat Biotech International Limited A vaccine for chikungunya virus infection
BRPI1012635A2 (en) 2009-03-27 2016-06-21 Academia Sinica "methods and compositions for virus immunization"
US20100310656A1 (en) 2009-04-27 2010-12-09 Immunitor USA, Inc. Immunotherapy and prevention of autoimmune hepatitis
EA201391515A1 (en) 2011-05-26 2014-05-30 Глаксосмитклайн Байлоджикалс С.А. INACTIVATED DENGE VIRUS VACCINE
AU2012269907B2 (en) 2011-06-17 2017-05-18 Bharat Biotech International Limited Vaccine composition comprising an inactivated chikungunya virus strain
SI3106176T1 (en) 2011-12-06 2018-04-30 Valneva Austria Gmbh Aluminium compounds for use in therapeutics and vaccines
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
JP2015509963A (en) 2012-03-08 2015-04-02 ノバルティス アーゲー Combination vaccine containing a TLR4 agonist
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
AU2014338520B2 (en) 2013-09-14 2019-12-05 Bharat Biotech International Limited A viral vaccine and methods of manufacture thereof
SG11201702116VA (en) 2014-09-17 2017-04-27 Univ Iowa Res Found Viral rna segments as immunomodulatory agents and vaccine components
CU24510B1 (en) 2014-10-07 2021-05-12 Serum Institute Of India Pvt Ltd METHOD FOR THE COMPOSITION OF A VACCINE AGAINST POLIOMYELITIS, WITH INACTIVATED POLIOVIRUSES AND ADSORPTION IN COADJUVANTS
AR102547A1 (en) 2014-11-07 2017-03-08 Takeda Vaccines Inc VACCINES AGAINST DISEASE OF HANDS, FEET AND MOUTH AND MANUFACTURING METHODS AND THEIR USE
WO2016145149A1 (en) 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
US20180185467A1 (en) 2015-06-22 2018-07-05 President And Fellows Of Harvard College Compositions and methods for modulating viral infection
WO2017009873A1 (en) * 2015-07-16 2017-01-19 Bharat Biotech International Limited Vaccine compositions
ES2937963T3 (en) 2015-07-21 2023-04-03 Modernatx Inc Infectious disease vaccines
WO2017056094A1 (en) 2015-09-30 2017-04-06 Ramot At Tel-Aviv University Ltd. Attenuated virus mutated at sites of evolutionarily conserved rna structure
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. Tropical disease vaccines
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
FI3393510T3 (en) 2015-12-23 2023-03-22 Valneva Austria Gmbh Zika virus vaccine
US11434259B2 (en) 2016-01-25 2022-09-06 Iogenetics, Llc Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
CN109152826B (en) 2016-02-25 2022-11-04 宾夕法尼亚大学理事会 Novel vaccine against Zika virus
US20170354729A1 (en) 2016-03-16 2017-12-14 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
CN105749268B (en) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 Inactivated Zika virus vaccine
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
WO2017192856A1 (en) 2016-05-04 2017-11-09 University Of Miami Zika virus vector for treating zika virus infection
AU2017261705B2 (en) 2016-05-10 2024-04-18 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
US10967057B2 (en) 2016-06-02 2021-04-06 Glaxosmithkline Biologicals S.A. Zika viral antigen constructs
BR112018075440A2 (en) 2016-06-09 2019-04-02 Beth Israel Deaconess Medical Center compositions and methods for preventing and treating Zika virus infection
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
BR112018075513A2 (en) 2016-06-13 2019-10-01 Us Health nucleic acids encoding Zika virus-like particles and their use in vaccines and Zika virus diagnostic testing
US10632185B2 (en) 2016-07-08 2020-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric west nile/zika viruses and methods of use
BR112018077041A2 (en) 2016-07-08 2019-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale genomic sequences coding for a mutant-acting Zika virus
US11834494B2 (en) 2016-07-26 2023-12-05 Washington University Antibodies to zika virus and methods of use thereof
GB201613191D0 (en) 2016-07-29 2016-09-14 Univ Oxford Innovation Ltd Zika virus vaccine
US11780885B2 (en) 2016-11-17 2023-10-10 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
US20190358313A1 (en) 2016-12-23 2019-11-28 Expres2Ion Biotechnologies Aps New flavivirus vaccine
CN108503697B (en) 2017-02-27 2023-03-31 中国科学院上海巴斯德研究所 Zika virus subunit vaccine expressed by drosophila cells
CN108503696B (en) 2017-02-27 2023-05-12 中国科学院上海巴斯德研究所 Zika virus subunit vaccine expressed by yeast cells
EP4205760A1 (en) 2017-03-08 2023-07-05 University of Georgia Research Foundation, Inc. Methods and compositions related to increased viral production
WO2018187799A1 (en) 2017-04-07 2018-10-11 The Rockefeller University Compositions and methods related to human neutralizing antibodies to zika and dengue 1 virus
WO2018237039A1 (en) 2017-06-20 2018-12-27 Texas Tech University System Zika virus like particle (vlp) based vaccine and microneutralization assay
EP3417943B1 (en) 2017-06-21 2020-02-12 Eppendorf AG Centrifuge rotor with seal
CN107188935B (en) * 2017-07-20 2018-10-02 北京健乃喜生物技术有限公司 A kind of zika virus NS1 antigenic mutants and its application
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
CN107537029B (en) 2017-09-14 2021-03-19 北京科兴生物制品有限公司 Zika virus and yellow fever virus combined inactivated vaccine
GB201716254D0 (en) 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
WO2019090228A2 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
BR102017024030A2 (en) 2017-11-08 2019-06-04 Universidade Federal De São João Del Rei IMMUNOGENIC RECOMBINANT PROTEIN WITH ZIKA ANTIGENS FOR VACCINE VIRUS AND ITS USES
WO2019104157A1 (en) 2017-11-21 2019-05-31 The University Of Vermont And State Agricultural College Highly specific zika neutralizing human antibodies
CN111601885A (en) 2017-11-30 2020-08-28 武田疫苗股份有限公司 Methods for inactivating Zika virus and related methods
CN108187036A (en) 2017-12-08 2018-06-22 北京科兴中维生物技术有限公司 A kind of zika virus combines inactivated vaccine with encephalitis B virus
CN108210921A (en) 2017-12-29 2018-06-29 广州恩宝生物医药科技有限公司 A kind of zika virus vaccine and preparation method thereof
BR112019020526A2 (en) 2018-02-22 2020-09-15 Nano4 Global, Lda method to detect flaviviridae
RU2020132280A (en) 2018-03-08 2022-04-11 Кодадженикс Инк. ATTENUATED FLAVIRUS
WO2019186199A1 (en) 2018-03-29 2019-10-03 Emergex Vaccines Holding Limited Vaccine compositions
KR102075581B1 (en) 2018-04-27 2020-02-10 가톨릭대학교 산학협력단 Adjuvant comprising nucleic acid molecule inserted viral expression regulation sequence and phamraceutical composition having the adjuvant
WO2020017765A1 (en) 2018-07-18 2020-01-23 (주)진매트릭스 Zika virus variant and zika vaccine composition comprising same
WO2020051766A1 (en) 2018-09-11 2020-03-19 上海市公共卫生临床中心 Immunogen for broad-spectrum influenza vaccine and application thereof
US20210308250A1 (en) 2018-10-26 2021-10-07 New York Blood Center, Inc. Zika virus immunogenic compositions
JP7463366B2 (en) 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド Novel anti-Zika virus antibodies and uses thereof
EP3965811A1 (en) 2019-05-08 2022-03-16 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
WO2021262659A1 (en) 2020-06-22 2021-12-30 University Of Connecticut Flavivirus signal peptides, vaccine constructs, and methods therefor

Also Published As

Publication number Publication date
AU2022201109B9 (en) 2022-05-12
US11648304B2 (en) 2023-05-16
BR112020008665A2 (en) 2020-11-10
US20210177958A1 (en) 2021-06-17
MX2020004367A (en) 2020-10-19
SG11202003949TA (en) 2020-05-28
AU2018359556B2 (en) 2021-12-02
AU2022209239A1 (en) 2022-08-18
EP3703740A2 (en) 2020-09-09
KR20200117981A (en) 2020-10-14
AU2022201109A1 (en) 2022-03-10
CN111526885A (en) 2020-08-11
WO2019090228A2 (en) 2019-05-09
WO2019090233A2 (en) 2019-05-09
JP2023175761A (en) 2023-12-12
US11478541B2 (en) 2022-10-25
MX2020004543A (en) 2020-09-18
JP2021502075A (en) 2021-01-28
WO2019090238A1 (en) 2019-05-09
SG11202003796XA (en) 2020-05-28
MY193736A (en) 2022-10-27
AU2018359558A1 (en) 2020-05-28
US11730802B2 (en) 2023-08-22
AU2022209239B2 (en) 2023-10-05
AU2022201109B2 (en) 2022-04-28
US20210177959A1 (en) 2021-06-17
MX2020004542A (en) 2020-09-18
AU2018359660A1 (en) 2020-05-28
US20230145065A1 (en) 2023-05-11
MY194449A (en) 2022-11-30
AU2018359556A1 (en) 2020-05-28
KR20200085302A (en) 2020-07-14
AU2022203422B2 (en) 2023-10-05
AU2018359558C1 (en) 2022-09-22
JP7443232B2 (en) 2024-03-05
CN111615397A (en) 2020-09-01
CN111511395A (en) 2020-08-07
CA3081581A1 (en) 2019-05-09
AU2018359660B2 (en) 2022-02-24
US20200360505A1 (en) 2020-11-19
EP3703741A1 (en) 2020-09-09
KR20200083571A (en) 2020-07-08
JP2021502350A (en) 2021-01-28
WO2019090228A3 (en) 2019-06-20
JP7295124B2 (en) 2023-06-20
US20230414743A1 (en) 2023-12-28
BR112020008652A2 (en) 2020-11-10
EP3703739A2 (en) 2020-09-09
AU2022203422A1 (en) 2022-06-09
CA3081586A1 (en) 2019-05-09
AU2018359558B2 (en) 2021-12-02
BR112020008693A2 (en) 2020-10-13
US11964008B2 (en) 2024-04-23
CA3081578A1 (en) 2019-05-09
JP2021505648A (en) 2021-02-18
WO2019090233A3 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
SG11202003796XA (en) Zika vaccines and immunogenic compositions, and methods of using the same
HUS2200035I1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HK1250136A1 (en) Vaccine compositions having improved stability and immunogenicity
SG11202004863QA (en) Zika vaccines and immunogenic compositions, and methods of using the same
IL268168A (en) Immunogenic compositions for use in pneumococcal vaccines
ZA202000889B (en) An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
IL269590A (en) Methods and compositions for reduction of immunogenicity
IL251120A0 (en) Immunogenic/therapeutic glycoconjugate compositions and uses thereof
SG11201803581VA (en) Chimeric RSV, Immunogenic Compositions, and Methods of Use
GB201721582D0 (en) S aureus antigens and immunogenic compositions
EP3307311A4 (en) Multivalent enterovirus vaccine compositions and uses related thereto
IL271603A (en) Immunogenic compositions
IL258700A (en) Adjuvant and vaccine composition containing the same
GB2570806B (en) Immunogenic agent and associated compositions, uses and methods
GB201911959D0 (en) Immunogenic compositions and uses therefor
SG11202004167XA (en) Immunogenic compositions and uses therefor
AU2017904540A0 (en) Immunogenic compositions and uses therefor
AU2014902031A0 (en) Immunogenic vaccines and uses thereof